EQT Life Sciences

Boston, Massachusetts

EQT Life Sciences, formerly LSP, is one of Europe’s largest and most experienced healthcare investors, targeting innovative life sciences and health care companies.

Founded:1986

Firm Location:Boston, Massachusetts • Brussels • Munich, Germany • Amsterdam, Netherlands • Germany • United Kingdom • Oxford, United Kingdom

Investor Firms That Co-Invest with EQT Life Sciences

New Enterprise Associates (NEA)Atlas Venture Founder Collective Polaris Partners VantagePoint Capital Partners Versant Ventures Pfizer Venture Investments SR One Novartis Venture Fund F-Prime Capital Partners Earlybird Venture Capital Aperture Venture Partners RA Capital Management U.S. Venture Partners (USVP)ARCH Venture Partners Abingworth OrbiMed Ysios Capital TheVentureCity Pivotal bioVenture Partners Illumina Ventures Stanley Ventures MDC Ventures (formerly KBS Ventures)5am Ventures Casdin Capital Samsara BioCapital Mott Family Capital Kurma Partners Sanofi Ventures Mission BioCapital MP Healthcare Venture Management Pontifax Venture Capital Forbion Andera Partners Business Growth Fund Advent Life Sciences Atlantic Bridge Seroba Life Sciences Catalio Capital Management Sofinnova Partners Earlybird Health Tech Osage University Partners (OUP)Syncona Limited EQT Group Signet Healthcare Partners Pappas Capital

EQT Life Sciences Team

Fouad Azzam

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Boston (MA)

Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists)

to see your intro paths to Fouad

Philipp Bräuer

EQT Life Sciences·Associate

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Munich (Germany)

Investors in BioTech (Seed), Investors in Health IT (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)

to see your intro paths to Philipp

Christoph Broja

EQT Life Sciences·Managing Director

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Germany

Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Diagnostics (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Health IT (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)

to see your intro paths to Christoph

Drew Burdon

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in United Kingdom

Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series A)

to see your intro paths to Drew

Arno de Wilde

EQT Life Sciences·Investor

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

to see your intro paths to Arno

Laurenz Govaerts

EQT Life Sciences·Vice President

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Brussels

to see your intro paths to Laurenz

Sonia Hallen

EQT Life Sciences·Vice President

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

Investors in BioTech (Seed), Investors in BioTech (Pre-seed)

to see your intro paths to Sonia

Kevin Hammon

EQT Life Sciences·Associate

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Health IT (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)

to see your intro paths to Kevin

Bruno Holthof

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Oxford (United Kingdom)

to see your intro paths to Bruno

Cillian King

EQT Life Sciences·Managing Director

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Diverse Investors (Other Lists), Investors in BioTech (Series A)

to see your intro paths to Cillian

Martijn Kleijwegt

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

Investors in BioTech (Series A)

to see your intro paths to Martijn

René Kuijten

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B)

to see your intro paths to René

Maximilian Moser

EQT Life Sciences·Associate

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

to see your intro paths to Maximilian

Geraldine O'Keeffe

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

Investors in Health IT (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)

to see your intro paths to Geraldine

Anne Portwich

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A)

to see your intro paths to Anne

Joachim Rothe

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Munich (Germany)

Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series A)

to see your intro paths to Joachim

Philip Scheltens

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

Investors in BioTech (Series B)

to see your intro paths to Philip

Clemens van Blitterswijk

EQT Life Sciences·Venture Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

to see your intro paths to Clemens

Mark Wegter

EQT Life Sciences·Partner

Sweet spot: $25.0M

Range: $11.0M - $65.0M

Investors in Amsterdam (Netherlands)

Investors in BioTech (Seed), Investors in BioTech (Pre-seed)

to see your intro paths to Mark